The DTWD1 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population for loss-of-function analysis of DTWD1. This product comprises a heterogeneous pool of NCI-H1299 non-small cell lung carcinoma cells with CRISPR/Cas9-mediated disruptions in the DTWD1 gene. The polyclonal format allows population-level assessment of gene function, minimizing clonal artifacts while preserving knockout diversity. It is a valuable tool for investigating the uncharacterized DTW domain-containing protein 1 in cancer cell biology.
NCI-H1299 is an adherent epithelial cell line derived from lymph node metastasis of a non-small cell lung adenocarcinoma, widely used in cancer research. It harbors wild-type TP53 and a KRAS G12C mutation, providing a relevant model for studying KRAS-driven lung adenocarcinoma. These cells are well-established for examining apoptosis, metastasis, and drug response, making them particularly suitable for oncogenic signaling and resistance studies.
DTWD1 encodes a DTW domain-containing protein predicted to function in tRNA modification or RNA metabolism, though its exact role is unknown. It is hypothesized to act in pathways alongside tRNA modification enzymes such as TRMT5 and TRIT1, and is predicted to interact with mitochondrial ribosomal proteins. Disruption of DTWD1 may therefore affect RNA modification states, potentially influencing mitochondrial translation and overall protein synthesis, with downstream effects on cell proliferation and metabolic fitness.
In the NCI-H1299 lung adenocarcinoma background, DTWD1 knockout provides a platform to explore its role in cancer cell biology. Given the KRAS G12C mutation, this model is ideal for assessing whether DTWD1 contributes to oncogenic processes or identifies metabolic dependencies. The polyclonal knockout population can reveal how RNA modification perturbations impact proliferation, apoptosis, and therapeutic response, offering insights into potential vulnerabilities in KRAS-mutant tumors.
Research applications encompass functional characterization of DTWD1, elucidation of RNA modification pathways, drug sensitivity profiling, and synthetic lethality screens. Assays include western blotting, RT-qPCR, RNA-seq, cell viability (MTT, CellTiter-Glo), apoptosis (Annexin V), migration and invasion, mitochondrial function, and co-immunoprecipitation for interactor discovery. These polyclonal knockout cells provide a comprehensive toolset for studying DTWD1 in lung adenocarcinoma. For inquiries, contact Ascent Research.
